BANGALORE, May 28 (Reuters) - Introgen Therapeutics Inc said its experimental gene therapy, Advexin, met goals in a late-stage head and neck cancer study, but shares fell as the drug did not improve survival in certain patients.
BANGALORE, May 28 (Reuters) - Introgen Therapeutics Inc said its experimental gene therapy, Advexin, met goals in a late-stage head and neck cancer study, but shares fell as the drug did not improve survival in certain patients.
